{"id":"W3034621686","doi":"10.1136/annrheumdis-2020-eular.2059","title":"SAT0151 EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Abatacept; Rheumatoid arthritis; Internal medicine; Clinical endpoint; Adalimumab; Adverse effect; Methotrexate; Tofacitinib; Clinical trial; Gastroenterology; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001312324,0.0004578814,0.003043324,0.000284856,0.0001455386,0.00005743196,0.0003249512,0.00009223618,0.00005825531],"category_scores_gemma":[0.0219496,0.0002612088,0.0003155907,0.0007745132,0.0007424182,0.0002226937,0.000255534,0.0002358117,0.000003377456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003152218,"about_ca_system_score_gemma":0.002888496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000172089,"about_ca_topic_score_gemma":0.00001793176,"domain_scores_codex":[0.9950833,0.001237134,0.001590788,0.0005978844,0.0009423791,0.0005484707],"domain_scores_gemma":[0.9885249,0.008991554,0.0008476894,0.0005728957,0.0003490719,0.0007139352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9488894,0.001244675,0.0002308539,0.0008784792,0.0009323325,0.00001351465,0.002722017,0.00008803107,0.00001533216,0.00002054854,0.00003957632,0.04492519],"study_design_scores_gemma":[0.9778271,0.00334648,0.00822339,0.006176628,0.0003068104,0.000002838112,0.0004372127,0.003100986,0.0002502191,0.00003197147,0.000009650467,0.0002867345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824097,0.002632997,0.00003638882,0.002122578,0.00007390356,0.01248323,0.0001900643,0.00003736966,0.00001380228],"genre_scores_gemma":[0.9960586,0.003028345,0.00007513257,0.0001977959,0.00001824094,0.0005288513,0.00003821015,0.00004255783,0.00001230455],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04463845,"threshold_uncertainty_score":0.999984,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05963422971722983,"score_gpt":0.3616093117384592,"score_spread":0.3019750820212294,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}